Published in Mol Cell Biol on December 01, 1998
Anaplastic lymphoma kinase: signalling in development and disease. Biochem J (2009) 3.05
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci U S A (2005) 2.94
Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood (2007) 2.65
An efficient rapid system for profiling the cellular activities of molecular libraries. Proc Natl Acad Sci U S A (2006) 2.51
Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood (2005) 2.15
Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther (2009) 1.73
Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J Clin Invest (2006) 1.51
Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro Oncol (2011) 1.26
Novel ALK inhibitors in clinical use and development. J Hematol Oncol (2015) 1.24
Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas. Immunology (2005) 1.23
Development of treatment strategies for advanced neuroblastoma. Int J Clin Oncol (2012) 1.22
Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells. Blood (2006) 1.22
Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan. PLoS One (2013) 1.21
Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage. Mol Cell Biol (2006) 1.19
p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. Blood (2005) 1.16
Aberrant ALK tyrosine kinase signaling. Different cellular lineages, common oncogenic mechanisms. Am J Pathol (2000) 1.05
Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity. Am J Pathol (2002) 0.99
OTX2 represses myogenic and neuronal differentiation in medulloblastoma cells. Cancer Res (2012) 0.98
IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells. Blood (2009) 0.98
C/EBPβ expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway. Haematologica (2009) 0.98
NPM-ALK signals through glycogen synthase kinase 3β to promote oncogenesis. Oncogene (2011) 0.95
ALK-immunoreactive neoplasms. Int J Clin Exp Pathol (2012) 0.93
The neuroblastoma ALK(I1250T) mutation is a kinase-dead RTK in vitro and in vivo. Transl Oncol (2011) 0.91
Identification of C/EBPβ target genes in ALK+ anaplastic large cell lymphoma (ALCL) by gene expression profiling and chromatin immunoprecipitation. PLoS One (2013) 0.89
ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma. Front Oncol (2012) 0.88
The nucleophosmin-anaplastic lymphoma kinase fusion protein induces c-Myc expression in pediatric anaplastic large cell lymphomas. Am J Pathol (2002) 0.86
Evaluation of retinoic acid therapy for OTX2-positive medulloblastomas. Neuro Oncol (2010) 0.86
Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation. J Pathol (2015) 0.85
Molecular and functional characterizations of the association and interactions between nucleophosmin-anaplastic lymphoma kinase and type I insulin-like growth factor receptor. Neoplasia (2013) 0.83
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma. Blood (2007) 0.83
The nucleophosmin-anaplastic lymphoma kinase oncogene interacts, activates, and uses the kinase PIKfyve to increase invasiveness. J Biol Chem (2011) 0.83
Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma. Curr Opin Hematol (2013) 0.82
The ALK inhibitor ASP3026 eradicates NPM-ALK⁺ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model. Oncotarget (2014) 0.82
Functional characterization of the kinase activation loop in nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) using tandem affinity purification and liquid chromatography-mass spectrometry. J Biol Chem (2009) 0.82
Studies of phosphoproteomic changes induced by nucleophosmin-anaplastic lymphoma kinase (ALK) highlight deregulation of tumor necrosis factor (TNF)/Fas/TNF-related apoptosis-induced ligand signaling pathway in ALK-positive anaplastic large cell lymphoma. Mol Cell Proteomics (2010) 0.80
NPM-ALK up-regulates iNOS expression through a STAT3/microRNA-26a-dependent mechanism. J Pathol (2013) 0.80
Genetics of anaplastic large cell lymphoma. Leuk Lymphoma (2015) 0.79
The tyrosine 343 residue of nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) is important for its interaction with SHP1, a cytoplasmic tyrosine phosphatase with tumor suppressor functions. J Biol Chem (2010) 0.78
NPM-ALK phosphorylates WASp Y102 and contributes to oncogenesis of anaplastic large cell lymphoma. Oncogene (2016) 0.78
Constitutive control of AKT1 gene expression by JUNB/CJUN in ALK+ anaplastic large-cell lymphoma: a novel crosstalk mechanism. Leukemia (2015) 0.77
Anaplastic lymphoma kinase regulates binge-like drinking and dopamine receptor sensitivity in the ventral tegmental area. Addict Biol (2016) 0.77
Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs. Cell Mol Life Sci (2016) 0.77
CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma. Oncotarget (2016) 0.75
Research progresses in the pathogenesis of anaplastic large cell lymphoma. Chin J Cancer (2011) 0.75
Cell kinetics and cell cycle regulation in lymphomas. J Clin Pathol (2002) 0.75
Sensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy. PLoS One (2016) 0.75
[Viennese Clinical Weekly Review]. Wien Klin Wochenschr (2013) 0.75
Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene (1988) 52.71
Signal transduction by receptors with tyrosine kinase activity. Cell (1990) 22.72
SH2 domains recognize specific phosphopeptide sequences. Cell (1993) 17.28
SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. Science (1991) 12.93
Protein modules and signalling networks. Nature (1995) 12.53
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science (1994) 10.45
Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell (1989) 7.21
Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell (1985) 6.06
Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature (1984) 4.30
PDGF stimulation of inositol phospholipid hydrolysis requires PLC-gamma 1 phosphorylation on tyrosine residues 783 and 1254. Cell (1991) 3.95
Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature (1984) 3.24
SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: identification of Tyr992 as the high-affinity binding site for SH2 domains of phospholipase C gamma. EMBO J (1992) 2.82
Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene (1997) 2.80
ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK) Oncogene (1997) 2.44
Characterization of the cDNA encoding human nucleophosmin and studies of its role in normal and abnormal growth. Biochemistry (1989) 2.12
Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol (1997) 2.04
An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias. EMBO J (1993) 2.00
Overlapping cDNA clones define the complete coding region for the P210c-abl gene product associated with chronic myelogenous leukemia cells containing the Philadelphia chromosome. Proc Natl Acad Sci U S A (1986) 1.97
CD30-positive large cell lymphomas ('Ki-1 lymphoma') are associated with a chromosomal translocation involving 5q35. Br J Haematol (1990) 1.93
Tyrosines 1021 and 1009 are phosphorylation sites in the carboxy terminus of the platelet-derived growth factor receptor beta subunit and are required for binding of phospholipase C gamma and a 64-kilodalton protein, respectively. Mol Cell Biol (1993) 1.88
Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood (1997) 1.83
Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell (1995) 1.73
Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc Natl Acad Sci U S A (1996) 1.72
Neuronal differentiation signals are controlled by nerve growth factor receptor/Trk binding sites for SHC and PLC gamma. EMBO J (1994) 1.68
Phosphoinositide-specific phospholipase C and mitogenic signaling. Biochim Biophys Acta (1995) 1.61
Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med (1995) 1.59
Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol Cell Biol (1995) 1.57
Src homology 2 domain as a specificity determinant in the c-Abl-mediated tyrosine phosphorylation of the RNA polymerase II carboxyl-terminal repeated domain. Proc Natl Acad Sci U S A (1995) 1.52
Cloning and characterization of GRB14, a novel member of the GRB7 gene family. J Biol Chem (1996) 1.52
Nuclear magnetic resonance structure of an SH2 domain of phospholipase C-gamma 1 complexed with a high affinity binding peptide. Cell (1994) 1.48
Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene (1994) 1.41
Interaction of nucleolar phosphoprotein B23 with nucleic acids. Biochemistry (1989) 1.37
The cloning of Grb10 reveals a new family of SH2 domain proteins. Oncogene (1995) 1.35
The human leukemia oncogene bcr-abl abrogates the anchorage requirement but not the growth factor requirement for proliferation. Mol Cell Biol (1995) 1.34
Phosphorylation sites at the C-terminus of the platelet-derived growth factor receptor bind phospholipase C gamma 1. Mol Biol Cell (1993) 1.24
DNA cloning and amino acid sequence determination of a major constituent protein of mammalian nucleoli. Correspondence of the nucleoplasmin-related protein NO38 to mammalian protein B23. Chromosoma (1988) 1.19
The nature of Hodgkin and Reed-Sternberg cells, their association with EBV, and their relationship to anaplastic large-cell lymphoma. Ann Oncol (1991) 1.10
Oncogenic activation of tyrosine kinases. Curr Opin Genet Dev (1994) 1.04
Inhibition of FGF-stimulated phosphatidylinositol hydrolysis and neurite outgrowth by a cell-membrane permeable phosphopeptide. Curr Biol (1996) 1.04
Chronic myelomonocytic leukemia: Tel-a-kinase what Ets all about. Cell (1994) 1.00
Ki-1/CD30+ (anaplastic) large-cell lymphoma: maturation of a clinicopathologic entity with prospects of effective therapy. J Clin Oncol (1994) 0.96
Complete cDNA encoding a putative phospholipase C from transformed human lymphocytes. FEBS Lett (1988) 0.89
Human ltk receptor tyrosine kinase binds to PLC-gamma 1, PI3-K, GAP and Raf-1 in vivo. Oncogene (1994) 0.85
PLC-gamma activation is required for PDGF-betaR-mediated mitogenesis and monocytic differentiation of myeloid progenitor cells. Oncogene (1997) 0.83
Growth and survival signals transmitted via two distinct NPXY motifs within leukocyte tyrosine kinase, an insulin receptor-related tyrosine kinase. J Biol Chem (1996) 0.81
Activation of phospholipase C is not correlated to the formation of prostaglandins and superoxide in cultured rat liver macrophages. Cell Signal (1991) 0.80
The control of inositol lipid hydrolysis. Cancer Surv (1996) 0.78
Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood (1999) 2.95
Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study. Am J Surg Pathol (2001) 2.80
Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nat Genet (2001) 2.55
Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood (2001) 2.50
I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat Biotechnol (1997) 2.47
ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood (1998) 2.41
Differences in the state of differentiation of THP-1 cells induced by phorbol ester and 1,25-dihydroxyvitamin D3. J Leukoc Biol (1996) 2.35
IFN-gamma stimulates IgG2a secretion by murine B cells stimulated with bacterial lipopolysaccharide. J Immunol (1988) 2.24
The emerging normal and disease-related roles of anaplastic lymphoma kinase. Cell Mol Life Sci (2004) 2.19
Anaplastic lymphoma kinase proteins in growth control and cancer. J Cell Physiol (2004) 2.19
Informatics and medicine--from molecules to populations. Methods Inf Med (2008) 2.13
Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol (1997) 2.04
Two membrane-associated NiFeS-carbon monoxide dehydrogenases from the anaerobic carbon-monoxide-utilizing eubacterium Carboxydothermus hydrogenoformans. J Bacteriol (2001) 2.00
Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32). Nat Genet (1999) 1.96
Development and geometry of isotropic and directional shrinkage-crack patterns. Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics (2000) 1.88
The anticancer drug imatinib induces cellular autophagy. Leukemia (2007) 1.84
Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood (1997) 1.83
A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. Blood (1997) 1.82
Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol (2000) 1.75
Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am J Pathol (2001) 1.72
A locus for bipolar affective disorder on chromosome 4p. Nat Genet (1996) 1.67
The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. Oncogene (1996) 1.65
Translocations involving anaplastic lymphoma kinase (ALK). Oncogene (2001) 1.61
Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res (2001) 1.60
Effects of B cell stimulatory factor-1/interleukin 4 on hematopoietic progenitor cells. Blood (1987) 1.56
Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood (2000) 1.51
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia (2005) 1.48
Automation of genetic linkage analysis using fluorescent microsatellite markers. Genomics (1994) 1.43
Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial. Br J Cancer (2008) 1.42
Interferon-alpha stimulates production of interleukin-10 in activated CD4+ T cells and monocytes. Blood (1996) 1.41
DNA restriction fragment length polymorphisms as markers of familial coronary heart disease. Lancet (1989) 1.40
Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer (2010) 1.38
Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol (2007) 1.38
Chromosomal assignment and genomic structure of Il15. Genomics (1995) 1.31
Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. Br J Cancer (2005) 1.31
Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines. Blood (2000) 1.29
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science (1995) 1.27
Interacting haplotypes at the NPAS3 locus alter risk of schizophrenia and bipolar disorder. Mol Psychiatry (2008) 1.27
Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia (2011) 1.26
Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia (2004) 1.26
Association of Neuregulin 1 with schizophrenia and bipolar disorder in a second cohort from the Scottish population. Mol Psychiatry (2006) 1.23
The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol (2004) 1.18
Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial. Br J Cancer (2005) 1.15
Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. Br J Cancer (2003) 1.13
Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6-sIL-6R double transgenic mice. J Exp Med (1997) 1.13
Role of signal transducer and activator of transcription 5 in nucleophosmin/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells. Cancer Res (2001) 1.12
Cytogenetic and genetic evidence supports a role for the kainate-type glutamate receptor gene, GRIK4, in schizophrenia and bipolar disorder. Mol Psychiatry (2006) 1.12
Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27. Leukemia (2002) 1.11
Nucleolar localization of the nucleophosmin-anaplastic lymphoma kinase is not required for malignant transformation. Cancer Res (1998) 1.10
Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol (1997) 1.10
Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype. Exp Hematol (2000) 1.09
The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib. Leukemia (2006) 1.07
Rat hepatic sinusoidal endothelial cells in monolayer culture. Biochemical and ultrastructural characteristics. J Hepatol (1988) 1.07
Clinicopathologic features and treatment outcome of children with large-cell lymphoma and the t(2;5)(p23;q35). Blood (1994) 1.06
The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements. Am J Pathol (1997) 1.06
Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia. Leukemia (2005) 1.04
Hodgkin's disease: a tumor with disturbed immunological pathways. Immunol Today (1997) 1.03
Monoclonal antibodies to human myelomonocyte differentiation antigens in the diagnosis of acute myeloid leukemia. Med Oncol Tumor Pharmacother (1984) 1.03
Retracted Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation. Proc Natl Acad Sci U S A (1996) 1.03
Anaplastic lymphoma kinase proteins and malignancy. Curr Opin Hematol (2001) 1.03
Nucleophosmin (NPM) gene rearrangements in Ki-1-positive lymphomas. Cancer Res (1994) 1.02
Differential inhibition of prostaglandin and superoxide production by dexamethasone in primary cultures of rat Kupffer cells. Eur J Biochem (1986) 1.01
Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway. Oncogene (2009) 1.01
The cryptic inv(2)(p23q35) defines a new molecular genetic subtype of ALK-positive anaplastic large-cell lymphoma. Blood (1998) 1.00
Type-I interferons are potent inhibitors of interleukin-8 production in hematopoietic and bone marrow stromal cells. Blood (1993) 0.99
A transfected m5 muscarinic acetylcholine receptor stimulates phospholipase A2 by inducing both calcium influx and activation of protein kinase C. J Pharmacol Exp Ther (1990) 0.99
Localization of the gene encoding human BiP/GRP78, the endoplasmic reticulum cognate of the HSP70 family, to chromosome 9q34. Genomics (1994) 0.99
Constitutive activation of the MAPkinase p38 is critical for MMP-9 production and survival of B-CLL cells on bone marrow stromal cells. Leukemia (2004) 0.99
Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back. Leukemia (2003) 0.99
Human herpes virus 8 interleukin-6 homologue triggers gp130 on neuronal and hematopoietic cells. Eur J Biochem (2000) 0.98
The SH2-containing adapter protein GRB10 interacts with BCR-ABL. Oncogene (1998) 0.97
Myosin heavy chain kinase inactivated by Ca2+/calmodulin from aggregating cells of Dictyostelium discoideum. EMBO J (1983) 0.97
Molecular characterization of the gene for human interleukin-1 beta converting enzyme (IL1BC). Genomics (1994) 0.96
The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107. Leukemia (2005) 0.95
Far-red light irradiation of intact corn seedlings affects mitochondrial and calmodulin-dependent microsomal Ca2+ transport. Biochem Biophys Res Commun (1981) 0.95
The gene for PAX7, a member of the paired-box-containing genes, is localized on human chromosome arm 1p36. Genomics (1993) 0.95
Health resource consumption and costs attributable to chemotherapy-induced toxicity in German routine hospital care in lymphoproliferative disorder and NSCLC patients. Ann Oncol (2011) 0.95
The t(2;5) in human lymphomas. Leuk Lymphoma (1998) 0.94
The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia (2013) 0.94